ArticlePharmacoEconomics - open2023

Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States.

Aryana Sepassi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.